Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody –cytotoxic drug conjugate

ConclusionsT-DM1 exhibited preclinical activity in HER2-overexpressing BTC. Further evaluation in clinical studies is warranted.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research